Bridgewater Chapter Upcoming Events Join PCCI


Bio-Tree Systems Inc.

A new life sciences company bringing vascular informatics to oncology research, drug discovery and translational development

Presenters: Raul A. Brauner, Founder and CEO


Wednesday, January 21, 2015

Embassy Suites, Chesterbrook, Pennsylvania (directions)




Bio-Tree Systems, Inc. is the inventor of Vasculomics™, a novel life sciences and medical biomarker and informatics platform designed to detect and quantify 3D micro-vascular geometry / morphology patterns in various organs. The main purpose of Vasculomics™ is the identification, quantification, and correlation of 3D changes in the micro-vascular architecture of organ-based diseased regions with: disease presence (diagnostics), disease response to therapy (therapeutics), therapy personalization / optimization / monitoring, and, finally, drug development and drug-induced vascular toxicity. It is covered by over 40 pending and issued patents, with over 1,000 allowed claims. Their initial customer interactions started with drug discovery and pre-clinical projects conducted with large pharmaceutical companies in the area of oncology drug discovery of anti-cancer and anti-angiogenesis compounds.


Vasculomics™ enables precise 3D analysis of micro-vascular geometry / morphology architecture. It represents a brand new bio- and medical biomarker and informatics field that opens the possibility for significantly higher sensitivity and specificity, earlier detection and monitoring of over 50 disease classes, first and foremost expressed in micro-vascular changes. These include, the world’s top causes of mortality and morbidity: cardiovascular disease and stroke, chronic respiratory diseases (e.g. COPD), neurodegenerative diseases, diabetes complications, cancer and now, Opthalmology/Retina diseases. All together, these diseases had a $5 trillion impact on the world’s economies in 2010. This economic impact is expected to triple to over $15 trillion in the 2030-2050 period. (The World Economic Forum, the Global Economic Burden of Non-communicable Diseases Report, Sept. 2011)


Vasculomics™ will cover each targeted disease space from drug development (ranging from ex- vivo discovery to the in-vivo clinic), clinical disease screening and early detection (examples include: oncology - breast cancer, lung cancer, colorectal cancer, early onset of diabetic complications (nephropathy, neuropathy, retinopathy, etc.), early disease diagnosis (including the possibility for developing a novel, Vasculomics™-based class of clinical, patient-focused companion diagnosis), therapy optimization and personalization, etc.


By addressing the top mortality and morbidity causing chronic diseases, some of which affecting multiple organs (oncology, diabetes, fibrosis, inflammatory diseases, auto-immune diseases, etc.), Bio-Tree’s strategy is to target and leverage chronic diseases on an organ by organ basis. Examples include: the kidneys, involved in chronic kidney disease, diabetic nephropathy, kidney cancer, eye/retina in diabetic retinopathy, AMD, etc.; the brain, which is involved in neuro-thrombotic diseases (e.g. stroke), neurodegenerative diseases, diabetic complications, brain cancer, etc. Each targeted organ represents a “Vasculomics™ Organ-Platform” (VOP). These VOPs will become the foundation for organ-based disease applications and alliances with the world's leading diagnostics, drug and therapeutics developers, medical and research institutions and services providers.



3 Major Issues


  1. What would be alternative ways to bring Vasculomics™ to the market. We have chosen the Organ-based Platform approach whereby each organ is home to a number of diseases. We are also splitting the Pre-Clinical markets from the Clinical markets. This model is based on the way both drug development and medicine are being practiced today.
  2. What would be an ideal method to fund the development of Vasculomics™? We are currently pursuing funding Organ-specific independent clinical enterprises (e.g. a Lungs entity, a Retina entity, etc.), while, in the Pre-Clinical Drug Discovery we are gravitating toward a single Pre-Clinical enterprise. Each such Organ enterprise will be headed by a CEO whose goal would be to successfully develop the Organ-Vasculomics™ Clinical Business.
  3. We have also come up with the concept of a Vasculomics™-targeted Fund, as a mechanism to seed-fund (and perhaps co-fund the growth phase of) individual Organ-specific enterprises. What would the panel opinion be on this strategy?. Would it be feasible? Any reservations? Would PCCI and affiliated organization be open to work with Bio-Tree to create and co-manage such a fund?




6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)

8:00 - Raul A. Brauner, Founder and CEO of Bio-Tree, will deliver the Company's "Elevator" Pitch to the Group

8:20 - Panel will address three major issues crucial to helping the Company reach the next level.

9:00 - Open discussion: members and guests



Available Media

Please note: All information obtained here is the property of those presenting and should not be copied or duplicated without written consent.



None available at this time


Bio-Tree Systems Meeting Audio - 01/21/15


None available at this time


None available at this time

Contact Info:




Our Sponsors

EisnerAmperIdeas x Innovation Network i2nNew Jersey Institute of TechnologyScience Center


<Top of the page>





Questions or Coments?

Contact: Peter van der Kam, | (610) 296-8086




Good Company! Good Drink! Good Food! Good Program! Good Fun!


Site Navigation



Pharmaceutical Consulting Consortium International, Inc., or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2018



Tat Communication Inc